Managing insulin in type 2 diabetes just got a digital upgrade. The FDA has granted 510(k) clearance to MODI, a mobile app from DreaMed Diabetes that uses CGM and insulin data to automatically generate personalized dosing recommendations for adults with type 2 diabetes. It's the first app of its kind — and it works without requiring a healthcare provider to configure settings or sign off on each adjustment.

MODI is designed to tackle one of diabetes care's most stubborn problems: clinical inertia. Despite type 2 diabetes being a progressive disease that often eventually requires insulin, initiation and optimization of insulin therapy are frequently delayed by years — driven by fear of hypoglycemia, complex titration, and limited clinic access. MODI aims to bridge that gap by putting real-time, data-driven guidance directly in patients' hands between visits.

Key Takeaways:

• MODI supports both long-acting insulin users and those on multiple daily injections
• No HCP configuration or approval is needed for dose recommendations
• An ongoing 13-week trial (MODIUS) is evaluating safety outcomes including time in hypoglycemia and HbA1c change
• The FDA previously cleared Dexcom's Smart Basal for long-acting insulin titration in type 2 diabetes — MODI expands on that progress

Why it matters: Millions of insulin-dependent type 2 diabetes patients face delays in optimizing their therapy, raising the risk of serious complications. Tools like MODI could meaningfully reduce that gap by empowering patients to self-manage more effectively — and freeing up clinic resources in the process.